Analysts expect Cellectis (NASDAQ:CLLS) to post $9.53 million in sales for the current fiscal quarter, according to Zacks Investment Research. Three analysts have provided estimates for Cellectis’ earnings. The lowest sales estimate is $7.30 million and the highest is $11.29 million. Cellectis posted sales of $10.30 million in the same quarter last year, which suggests a negative year-over-year growth rate of 7.5%. The firm is expected to report its next quarterly earnings results on Tuesday, May 8th.
On average, analysts expect that Cellectis will report full-year sales of $36.57 million for the current financial year, with estimates ranging from $31.30 million to $41.98 million. For the next financial year, analysts anticipate that the firm will report sales of $47.77 million per share, with estimates ranging from $32.00 million to $77.10 million. Zacks Investment Research’s sales averages are a mean average based on a survey of research firms that that provide coverage for Cellectis.
Cellectis (NASDAQ:CLLS) last released its quarterly earnings results on Monday, March 12th. The biotechnology company reported ($0.76) EPS for the quarter, missing analysts’ consensus estimates of ($0.64) by ($0.12). Cellectis had a negative return on equity of 35.63% and a negative net margin of 298.01%. The firm had revenue of $6.91 million for the quarter, compared to analysts’ expectations of $10.10 million.
A number of equities analysts recently commented on the stock. BidaskClub cut shares of Cellectis from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, March 14th. Guggenheim assumed coverage on shares of Cellectis in a research note on Friday, March 16th. They set a “neutral” rating for the company. Nomura lifted their price target on shares of Cellectis to $73.00 and gave the stock a “buy” rating in a research note on Wednesday, March 14th. Zacks Investment Research cut shares of Cellectis from a “hold” rating to a “sell” rating in a research note on Wednesday, February 14th. Finally, ValuEngine raised shares of Cellectis from a “sell” rating to a “hold” rating in a research note on Friday, February 2nd. One analyst has rated the stock with a sell rating, three have given a hold rating and five have issued a buy rating to the company’s stock. Cellectis presently has an average rating of “Hold” and an average price target of $42.67.
Shares of CLLS stock traded down $0.34 during trading hours on Monday, reaching $29.71. 90,593 shares of the stock were exchanged, compared to its average volume of 637,604. Cellectis has a 12-month low of $21.25 and a 12-month high of $38.85. The stock has a market cap of $1,250.24, a PE ratio of -10.69 and a beta of 1.86.
A number of institutional investors have recently added to or reduced their stakes in CLLS. JPMorgan Chase & Co. purchased a new stake in Cellectis in the 3rd quarter valued at about $517,000. Wells Fargo & Company MN boosted its position in Cellectis by 77.8% in the 3rd quarter. Wells Fargo & Company MN now owns 16,983 shares of the biotechnology company’s stock valued at $483,000 after buying an additional 7,433 shares during the period. KBC Group NV purchased a new stake in Cellectis in the 3rd quarter valued at about $366,000. Eqis Capital Management Inc. purchased a new stake in Cellectis in the 4th quarter valued at about $748,000. Finally, Granite Point Capital Management L.P. purchased a new stake in Cellectis in the 4th quarter valued at about $1,458,000. 20.30% of the stock is owned by institutional investors.
ILLEGAL ACTIVITY WARNING: This report was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this report on another publication, it was copied illegally and reposted in violation of international copyright & trademark legislation. The original version of this report can be read at https://www.dispatchtribunal.com/2018/04/21/cellectis-clls-expected-to-post-quarterly-sales-of-9-53-million.html.
Cellectis SA, a clinical stage biotechnological company, develops and sells immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer in France. The company operates through two segments, Therapeutics and Plants. Its lead product candidate is UCART19, an allogeneic T-cell product candidate for the treatment of CD19 expressing hematologic malignancies, which develop in acute lymphoblastic leukemia (ALL).
Get a free copy of the Zacks research report on Cellectis (CLLS)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Cellectis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectis and related companies with MarketBeat.com's FREE daily email newsletter.